Skip to main content
Clinical Trials/NCT06162117
NCT06162117
Completed
Not Applicable

Validity and Reliability of the Two-Minute Step Test in Patients With Traumatic Meniscal Tear

Istanbul Physical Medicine Rehabilitation Training and Research Hospital2 sites in 1 country55 target enrollmentFebruary 21, 2024
ConditionsMeniscus Tear

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Meniscus Tear
Sponsor
Istanbul Physical Medicine Rehabilitation Training and Research Hospital
Enrollment
55
Locations
2
Primary Endpoint
Two-Minute Step Test
Status
Completed
Last Updated
last year

Overview

Brief Summary

This study is designed to explore the validity and reliability of the two-minute step test as an assessment method for functional capacity in patients diagnosed with traumatic meniscal tear. The objective is to determine the effectiveness of this test in accurately measuring the functional abilities of individuals with traumatic meniscus tears. By focusing on patients who have been diagnosed with such injuries and employing the two-minute step test, the study aims to provide valuable insights into the suitability of this evaluation tool for assessing functional capacity in this specific patient population. The findings of this research have the potential to contribute significantly to the clinical understanding and management of traumatic meniscal tears, offering clinicians a reliable and valid method for evaluating the functional capabilities of affected individuals.

Detailed Description

The study is planned as a cross-sectional clinical study. Fifty-five patients diagnosed with traumatic meniscal tear who apply to the Istanbul Physical Medicine and Rehabilitation Training and Research Hospital clinics will be included in the study. Patients must have a previous diagnosis of traumatic meniscal tear based on magnetic resonance imaging. Sociodemographic data such as age, height, weight, body mass index, marital status, education level, and occupation will be recorded. The level of impairment in daily activities of patients with meniscal tear will be assessed using the Western Ontario Meniscus Evaluation Questionnaire. Pain intensity will be evaluated using the Visual Analog Scale, a linear scale of 10 cm. The Pain Catastrophizing Scale will be used to assess the patient's level of distress due to pain. The patient's confidence level in performing different activities due to pain will be evaluated using the Pain Self-Efficacy Questionnaire. The patient's physical function will be assessed using the 2-Minute StepTest. This test, to be administered by the same evaluator, requires the patient to have rested for at least 30 minutes before starting, and there will be a minimum of 1 hour of rest between the tests conducted. Before starting the tests, the patient's blood pressure, oxygen saturation, and heart rate will be measured, and if results are outside the normal range, the test will not proceed.

Registry
clinicaltrials.gov
Start Date
February 21, 2024
End Date
March 21, 2024
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Istanbul Physical Medicine Rehabilitation Training and Research Hospital
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients aged between 18 and 50 who have previously been diagnosed with traumatic meniscal tear through magnetic resonance imaging will be included in the study

Exclusion Criteria

  • Patients under the age of 18 and over the age of 50
  • Patients with accompanying knee osteoarthritis
  • Degenerative meniscal tears
  • Uncontrolled hypertension
  • Decompensated cardiac failure
  • Presence of systemic diseases affecting lower limb functions
  • Presence of degenerative diseases affecting lower limb functions
  • Peripheral artery disease causing vascular claudication
  • Psychiatric illness
  • Neuromuscular disease

Outcomes

Primary Outcomes

Two-Minute Step Test

Time Frame: 0 day and 1th week

During the administration of the Two-Minute Step Test, the midpoint between the anterior superior iliac spine and the patella of the patient is marked. The patient is then instructed to take steps in place as quickly as possible for a duration of two minutes. The knee should be lifted at least to the level of the marked point. The number of steps taken by the patient within the two-minute period is recorded.

Secondary Outcomes

  • The Pain Self-Efficacy Questionnaire(0 day)
  • Western Ontario Meniscal Evaluation Tool(0 day)
  • Pain Catastrophizing Scale(0 day)
  • Visual Analogue Scale(0 day)

Study Sites (2)

Loading locations...

Similar Trials

Active, not recruiting
Not Applicable
Ensayo fase II para evaluar la eficacia y seguridad de catumaxomab como tratamiento de consolidación en pacientes con un cáncer epitelial de ovario en una segunda o tercera remisión completa
EUCTR2010-018478-19-ESGrupo Español de Investigación en Cáncer de Ovario - GEICO
Active, not recruiting
Not Applicable
Estudio para evaluar la eficacia y seguridad del tratamiento del estudio como primera linea de tratamiento en pacientes con cáncer gástrico Her 2 positivoCáncer GástricoMedDRA version: 14.0Level: LLTClassification code 10001150Term: Adenocarcinoma gastricSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2011-001231-23-ESFundación para el Progreso de la Oncología en Cantabria
Active, not recruiting
Not Applicable
Ensayo de fase II para evaluar la eficacia y la seguridad de panitumumab combinado con docetaxel y cisplatino como tratamiento de primera línea del adenocarcinoma gástrico o de la unión gastroesofágica en estadio avanzado - SPIGAEnsayo fase II para evaluar la eficacia y seguridad de panitumumab combinado con docetaxel y cisplatino como tratamiento de primera línea del adenocarcinoma gástrico o de la unión gastroesofágica en estado avanzado.
EUCTR2010-021192-87-ESGrupo Gallego de Investigación en Oncología - GGIO
Active, not recruiting
Phase 1
Essai de phase II évaluant l’efficacité et la tolérance de bevacizumab associé à une chimiothérapie dans le traitement de patients atteints de tumeurs endocrines digestives bien différenciées, progressives, localement avancées/métastatiques - BETTERTumeurs endocrines digestives et duodéno-pancréatiquesMedDRA version: 8.1Level: PTClassification code 10007279Term: Carcinoid tumour of the gastrointestinal tract
EUCTR2006-005144-84-FRRoche SAS81
Active, not recruiting
Phase 1
Estudio de fase II para evaluar la eficacia y la seguridad de la quimiorradioterapia con 5-fluorouracilo, mitomicina C y panitumumab como tratamiento del carcinoma anal de células escamosas
EUCTR2010-018430-48-ESGrupo Español Multidisciplinar en cáncer Digestivo-GEMCAD